15, 2015 /PRNewswire-USNewswire/ -- Drug overdose is the leading cause of injury death in the United States -- mostly due to abuse and misuse of prescription opioid pain relievers,
benzodiazepines (sedatives/tranquilizers), and stimulants.
Results show that past use of
benzodiazepines for three months or more was associated with an increased risk (up to 51%) of Alzheimer's disease.
The use of
benzodiazepines is common in older populations, ranging from 5% to 32% in community-dwelling older adults, (3) with incidence being much higher in aged care facilities.
BERLIN -- Chronic use of
benzodiazepines by elderly patients is associated with a 43%-51% increased risk of being diagnosed with Alzheimer's disease 5-10 years later, according to a large case-control study.
Alcohol was involved in nearly one-quarter of all opioid pain reliever--related deaths and just over 20% of deaths related to
benzodiazepines, according to a study of 2010 data released by the Food and Drug Administration and the Centers for Disease Control and Prevention.
A I think what you're referring to is some research that showed
benzodiazepines had been linked to Alzheimer's disease.
L'utilisation a long terme de certains somniferes ou medicaments contre l'anxiete de la famille des
benzodiazepines pourrait augmenter sensiblement le risque de developper une maladie d'Alzheimer, selon une etude franco-canadienne.
Furthermore, a number of unlicensed methods of administrating
benzodiazepines have been popularized and are currently in use worldwide.
The study conducted by researchers at Group Health Research Institute and the University of Washington (UW), also found that contrary to opioids - a class of medicines commonly given for pain,
benzodiazepines - a class of drugs generally given for insomnia and anxiety, did not affect pneumonia risk.
Compared to other compounds like alcohol and barbiturates working on GABAA receptors,
benzodiazepines are generally considered to have a higher margin of safety.
Pharmacotherapy includes the use of both antidepressant agents and
benzodiazepines.
Our results show for the first time that a nucleus deep in the middle of the brain generates a small protein product, or peptide, that acts just like
benzodiazepines.
